Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dodecanedioic acid (C-12) is a 12-carbon long-chain dicarboxylic acid that serves as an alternative energy substrate, particularly studied for its potential benefits in metabolic disorders such as type 2 diabetes mellitus and obesity. It is metabolized via $\beta$-oxidation to succinyl-CoA, which enters the citric acid cycle directly. This metabolic pathway is significant because it provides energy to skeletal muscle without stimulating insulin secretion or inhibiting lipolysis, which are common effects of glucose ingestion. By bypassing insulin-mediated glucose uptake, dodecanedioic acid can help maintain muscle glycogen stores and increase fatty acid utilization during physical exercise, potentially reducing muscle fatigue and improving metabolic flexibility in patients with impaired glucose metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dodecanedioic acid.